These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

436 related articles for article (PubMed ID: 36882218)

  • 21. Autoantibodies associated with systemic sclerosis in three autoimmune diseases imprinted by type I interferon gene dysregulation: a comparison across SLE, primary Sjögren's syndrome and systemic sclerosis.
    Andraos R; Ahmad A; Eriksson P; Dahlström Ö; Wirestam L; Dahle C; Hesselstrand R; Bengtsson AA; Jönsen A; Andréasson K; Sjöwall C
    Lupus Sci Med; 2022 Dec; 9(1):. PubMed ID: 36581379
    [TBL] [Abstract][Full Text] [Related]  

  • 22. TBK1: A key regulator and potential treatment target for interferon positive Sjögren's syndrome, systemic lupus erythematosus and systemic sclerosis.
    Bodewes ILA; Huijser E; van Helden-Meeuwsen CG; Tas L; Huizinga R; Dalm VASH; van Hagen PM; Groot N; Kamphuis S; van Daele PLA; Versnel MA
    J Autoimmun; 2018 Jul; 91():97-102. PubMed ID: 29673738
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prediction of autoimmune connective tissue disease in an at-risk cohort: prognostic value of a novel two-score system for interferon status.
    Md Yusof MY; Psarras A; El-Sherbiny YM; Hensor EMA; Dutton K; Ul-Hassan S; Zayat AS; Shalbaf M; Alase A; Wittmann M; Emery P; Vital EM
    Ann Rheum Dis; 2018 Oct; 77(10):1432-1439. PubMed ID: 29929956
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Serum type I interferon activity is dependent on maternal diagnosis in anti-SSA/Ro-positive mothers of children with neonatal lupus.
    Niewold TB; Rivera TL; Buyon JP; Crow MK
    Arthritis Rheum; 2008 Feb; 58(2):541-6. PubMed ID: 18240214
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Type I interferon pathway in pediatric systemic lupus erythematosus.
    Zhou Y; Song HM
    World J Pediatr; 2024 Jul; 20(7):653-668. PubMed ID: 38914753
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Type I Interferons in Systemic Autoimmune Rheumatic Diseases: Pathogenesis, Clinical Features and Treatment Options.
    Drougkas K; Skarlis C; Mavragani C
    Mediterr J Rheumatol; 2024 Jun; 35(Suppl 2):365-380. PubMed ID: 39193187
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Type I Interferon as cardiovascular risk factor in systemic and cutaneous lupus erythematosus: A systematic review.
    Kirchler C; Husar-Memmer E; Rappersberger K; Thaler K; Fritsch-Stork R
    Autoimmun Rev; 2021 May; 20(5):102794. PubMed ID: 33722754
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Distinct Functions of Autoantibodies Against Interferon in Systemic Lupus Erythematosus: A Comprehensive Analysis of Anticytokine Autoantibodies in Common Rheumatic Diseases.
    Gupta S; Tatouli IP; Rosen LB; Hasni S; Alevizos I; Manna ZG; Rivera J; Jiang C; Siegel RM; Holland SM; Moutsopoulos HM; Browne SK
    Arthritis Rheumatol; 2016 Jul; 68(7):1677-87. PubMed ID: 26815287
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Type I interferon in rheumatic diseases.
    Muskardin TLW; Niewold TB
    Nat Rev Rheumatol; 2018 Mar; 14(4):214-228. PubMed ID: 29559718
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Abnormalities of the type I interferon signaling pathway in lupus autoimmunity.
    Gallucci S; Meka S; Gamero AM
    Cytokine; 2021 Oct; 146():155633. PubMed ID: 34340046
    [TBL] [Abstract][Full Text] [Related]  

  • 31. An update on the role of type I interferons in systemic lupus erythematosus and Sjögren's syndrome.
    Thorlacius GE; Wahren-Herlenius M; Rönnblom L
    Curr Opin Rheumatol; 2018 Sep; 30(5):471-481. PubMed ID: 29889694
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Detection of anti-interferon antibodies in systemic lupus erythematosus.
    Suit BE; Axelrod D; Moutsopoulos HM; Decker JL; Hooks JJ
    Clin Exp Rheumatol; 1983; 1(2):133-5. PubMed ID: 6442634
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Higher activation of the interferon-gamma signaling pathway in systemic lupus erythematosus patients with a high type I IFN score: relation to disease activity.
    Liu M; Liu J; Hao S; Wu P; Zhang X; Xiao Y; Jiang G; Huang X
    Clin Rheumatol; 2018 Oct; 37(10):2675-2684. PubMed ID: 29774490
    [TBL] [Abstract][Full Text] [Related]  

  • 34. 2021 EULAR recommendations regarding lifestyle behaviours and work participation to prevent progression of rheumatic and musculoskeletal diseases.
    Gwinnutt JM; Wieczorek M; Balanescu A; Bischoff-Ferrari HA; Boonen A; Cavalli G; de Souza S; de Thurah A; Dorner TE; Moe RH; Putrik P; Rodríguez-Carrio J; Silva-Fernández L; Stamm T; Walker-Bone K; Welling J; Zlatković-Švenda MI; Guillemin F; Verstappen SMM
    Ann Rheum Dis; 2023 Jan; 82(1):48-56. PubMed ID: 35260387
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Potential role of RhoA GTPase regulation in type interferon signaling in systemic lupus erythematosus.
    Fan W; Wei B; Chen X; Zhang Y; Xiao P; Li K; Zhang YQ; Huang J; Leng L; Bucala R
    Arthritis Res Ther; 2024 Jan; 26(1):31. PubMed ID: 38243295
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Type I Interferons in the Pathogenesis and Treatment of Autoimmune Diseases.
    Jiang J; Zhao M; Chang C; Wu H; Lu Q
    Clin Rev Allergy Immunol; 2020 Oct; 59(2):248-272. PubMed ID: 32557263
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Autoantibodies to Cytosolic 5'-Nucleotidase 1A in Primary Sjögren's Syndrome and Systemic Lupus Erythematosus.
    Rietveld A; van den Hoogen LL; Bizzaro N; Blokland SLM; Dähnrich C; Gottenberg JE; Houen G; Johannsen N; Mandl T; Meyer A; Nielsen CT; Olsson P; van Roon J; Schlumberger W; van Engelen BGM; Saris CGJ; Pruijn GJM
    Front Immunol; 2018; 9():1200. PubMed ID: 29922285
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The role of cyclic GMP-AMP synthase and Interferon-I-inducible protein 16 as candidatebiomarkers of systemic lupus erythematosus.
    Fu Q; He Q; Dong Q; Xie J; Geng Y; Han H; Huang Y; Lu J; Zeng Z; Wang W; Chen K; Zhan X
    Clin Chim Acta; 2022 Jan; 524():69-77. PubMed ID: 34742679
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Type I Interferons in Systemic Lupus Erythematosus: A Journey from Bench to Bedside.
    Sim TM; Ong SJ; Mak A; Tay SH
    Int J Mol Sci; 2022 Feb; 23(5):. PubMed ID: 35269647
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Altered type II interferon precedes autoantibody accrual and elevated type I interferon activity prior to systemic lupus erythematosus classification.
    Munroe ME; Lu R; Zhao YD; Fife DA; Robertson JM; Guthridge JM; Niewold TB; Tsokos GC; Keith MP; Harley JB; James JA
    Ann Rheum Dis; 2016 Nov; 75(11):2014-2021. PubMed ID: 27088255
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.